S5 Ep19: Up Next: A Monthly Pill For PrEP? Px Pulse podcast

Content provided by Jeanne Baron and Px Pulse. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jeanne Baron and Px Pulse or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Px Pulse »
S5 Ep19: Up Next: A monthly pill for PrEP?

13d ago 14:38

MP3•Episode home

The drug maker Merck recently announced its plans to start two new trials, known as the EXPrESSIVE program, testing a monthly pill for PrEP. A once-a-month PrEP pill holds great potential for the field. Even with daily pills, a monthly ring, or long acting injectables such as cabotegravir and recently FDA-approved lenacapavir, there’ll be people who can’t find what they really need for prevention.
For advocates who follow prevention, there’s a lot to know about these trials, and powerful lessons to learn about Good Participatory Practice (GPP) and impactful involvement of stakeholders—especially community—in research. GPP has been a cornerstone of the process of design and protocol development for the EXPrESSIVE trials, and it doesn’t stop there.
This episode features Merck Senior Principal Scientist Rebeca Plank and AVAC’s Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials.

51 episodes

#Science #Jeanne Baron #Px Pulse